Isolation and Purification of Urinary Gonadotrophin Peptide
Author Information
Author(s): A. Kardana, M.E. Taylor, P.J. Southall, G.M. Boxer, A.J. Rowan, K.D. Bagshawe
Primary Institution: Cancer Research Campaign Laboratories, Charing Cross Hospital
Hypothesis
Can urinary gonadotrophin peptide (UGP) serve as a tumor marker?
Conclusion
UGP is present in higher levels in the urine of patients with certain neoplasms compared to healthy individuals.
Supporting Evidence
- UGP was isolated from urine samples of patients with different tumors.
- Immunohistochemical studies showed UGP reactivity in various neoplastic tissues.
- Healthy individuals also excreted UGP, but at significantly lower levels than cancer patients.
Takeaway
Researchers found a special protein in urine that can help detect some types of cancer. This protein is usually found in low amounts in healthy people but is much higher in those with certain tumors.
Methodology
The study involved isolating UGP from urine, using chromatography and immunohistochemistry to analyze its presence in various tissues.
Limitations
The study may not account for all types of tumors or variations in UGP levels across different populations.
Participant Demographics
Included patients with ovarian carcinoma, seminoma, and hydatidiform mole, as well as a healthy male control.
Want to read the original?
Access the complete publication on the publisher's website